Climax-run Dublin drug firm spins out
A Dublin-based drug discovery and development company, DS Biopharma, has spun out a new firm to focus on pulmonary disorders and fibrotic conditions.
The spin-out firm, Afimmune, is to continue the clinical development of a new anti-fibrotic compound called DS102.
Afimmune also has other compounds in pre-clinical development, according to the company.
"By spinning out DS102 into a new company, DS Biopharma can direct its full attention to developing products for inflammatory skin conditions," said Dr John Climax, chief executive. "Afimmune will focus on fibrotic conditions and pulmonary disorders."
Dr Climax is one of Ireland's best known drug development entrepreneurs, having built another company, Icon, into one of the world's biggest contract medical research companies over two decades.
DS Biopharma, headquartered in Leopardstpwn, is a privately held drug development company working on new medicines that improve the quality of life for people with diseases for which existing therapies are ineffective or unsafe. The company is currently developing drugs for dermatitis and inflammatory skin disorders.
Earlier this year, the firm announced plans to develop the anti-fibrotic and anti-inflammatory compound DS102 in chronic obstructive pulmonary disease patients as well as in non-alcoholic steatohepatitis patients.
"The additional positive preclinical data supports the anti-fibrotic and anti-inflammatory mechanisms previously observed with DS102 in murine model," said Dr Climax at the time. "The company is very encouraged by the potential utility of DS102."
He said that preclinical data suggested that DS102 is significantly sequestered in lung tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties in the same tissue after oral administration.